(Press-News.org) An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by researchers at Cedars-Sinai is safe and effective at helping people with moderate to severe ulcerative colitis reach clinical remission.
Results from the multicenter Phase II study, ARTEMIS-UC, were published in The New England Journal of Medicine.
Ulcerative colitis is a type of inflammatory bowel disease (IBD) that damages the digestive tract, causing stomach cramping, diarrhea, weight loss and rectal bleeding. It affects as many as 900,000 people in the U.S., and current treatments are often only minimally effective.
“Findings from this study are poised to have a remarkable impact on treatment for ulcerative colitis and IBD overall,” said study senior author and IBD research pioneer Stephan Targan, MD, the Feintech Family Chair in Inflammatory Bowel Disease and executive director of the F. Widjaja Inflammatory Bowel Disease Institute at Cedars-Sinai. “The investigational therapy was generated based on the concept of precision medicine; it shows promise as being both anti-inflammatory and anti-fibrotic; it represents a potential turning point in drug development and discovery; and it could change how this complex disease is treated in the future.”
The study evaluated a therapy developed by Cedars-Sinai clinician-scientists called tulisokibart (previously PRA023)—a man-made monoclonal antibody that acts like endogenous antibodies. It is designed to target and block a protein called TL1A, which can contribute to the severity of ulcerative colitis. The antibody reduces inflammation and targets fibrosis, which causes many of the complications and severity of disease.
“Unlike other IBD treatments that can exacerbate inflammation or suppress the body’s natural anti-inflammatory responses, our findings suggest that tulisokibart modulates inflammation and the body's anti-inflammatory mechanisms,” Targan said. “This dual action could lead to more balanced and effective management of ulcerative colitis.”
Notably, the role of TL1A as a master regulator of inflammation was discovered by Targan and collaborators at Cedars-Sinai. In groundbreaking work spanning two decades, the researchers found that while TL1A protects against invading pathogens, at high levels it also contributes to inflammation and fibrosis in IBD.
ARTEMIS-UC was a 12-week study involving 178 adults from 14 countries. It also included a genetic-based companion diagnostic test to help predict response to the therapy.
A Phase III study will further examine safety and test effectiveness of tulisokibart in patients who take it longer than 12 weeks.
Clinician-scientist and geneticist Dermot McGovern, MD, PhD, director of Translational Research in the F. Widjaja Inflammatory Bowel Disease Institute at Cedars-Sinai and one of the study authors, has focused his career on identifying genetic variants associated with ulcerative colitis and other autoimmune diseases, exploring drug targets and working to revolutionize treatment through a precision medicine approach.
Nearly 20 years ago at Oxford University, McGovern and colleagues, in the first-ever genome-wide association study in IBD, identified that a variation in the TNF superfamily 15 (TNFSF15) gene was associated with developing both ulcerative colitis and Crohn’s disease. The protein TL1A, simultaneously being studied by Targan at Cedars-Sinai, is encoded by TNFSF15. McGovern left Oxford to collaborate with Targan and team at Cedars-Sinai in the effort to bring scientific breakthroughs to IBD.
“Findings from the ARTEMIS-UC study exemplify how combining genetics and biology can transform IBD care,” said McGovern, the Joshua L. and Lisa Z. Greer Chair in Inflammatory Bowel Disease Genetics and the director of Precision Health at Cedars-Sinai.
McGovern, who was recently awarded the prestigious Sherman Prize for his pioneering work in advancing understanding of the genetic architecture of IBD in diverse populations, says the uniqueness of this target and the way tulisokibart was designed to interact with that target represent significant advancements in how clinicians approach IBD treatment.
“Previously we have only been able to prescribe a medication to a patient that we think will work well, but going forward we could imagine telling the patient, ‘Actually, the genetic test suggests that you would be more likely to respond to this therapy,’” McGovern said.
Targan and McGovern also noted that ARTEMIS-UC involved multiple countries and diverse populations, reflecting the global nature of IBD. The F. Widjaja Inflammatory Bowel Disease Institute has invested significant resources in extending genetic research in IBD to diverse populations.
“It’s taken a village—supported by Cedars-Sinai’s integrated science culture—to reach this point,” said Targan, a 2017 recipient of the Sherman Prize. “We’ve devoted our careers to getting better treatments to IBD patients, and now we’re closer than ever to helping all patients with ulcerative colitis get their disease into remission so they can get back to enjoying life.”
Other authors involved in the study include Bruce E. Sands, MD; Brian G. Feagan, MD; Laurent Peyrin-Biroulet, MD, PhD; Silvio Danese, MD; David T. Rubin, MD; Olivier Laurent, PhD; Allison Luo, MD; Deanna D. Nguyen, MD; Jiandong Lu, PhD; Mark Yen, MD; Jaroslaw Leszczyszyn, MD, PhD; Radosław Kempiński, MD, PhD; Christopher Ma, MD; and Timothy E. Ritter, MD.
This research was supported by Prometheus Biosciences, a subsidiary of MERCK.
Conflict of Interest: Targan and McGovern have consulted for MERCK, Prometheus Biosciences (acquired by MERCK) and Prometheus Labs.
END
NEJM: Results from targeted therapy for ulcerative colitis study
Phase ii study led by Cedars-Sinai demonstrates that monoclonal antibody treatment developed by Cedars-Sinai researchers is effective for moderate to severe ulcerative colitis
2024-09-25
ELSE PRESS RELEASES FROM THIS DATE:
Study finds certain MS therapies may not slow disability progression
2024-09-25
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, SEPTEMBER 25, 2024
MINNEAPOLIS – In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not receiving treatment. The study is published in the September 25, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
With MS, the body’s immune system attacks myelin, the fatty, white substance that insulates and protects the nerves. People with ...
Are gender and sexual identity linked to brain health?
2024-09-25
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, SEPTEMBER 25, 2024
MINNEAPOLIS – LGBTQ+ people may be more likely to have negative brain health outcomes, including a higher risk of dementia and late-life depression, than people who are cisgender and straight, according to a study published in the September 25, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology. These results do not prove that sexual or gender diversity causes neurological diseases, they only show an association.
LGBTQ+ refers to people who are lesbian, gay, bisexual, transgender, ...
The Academy of Science of St. Louis names Katherine Polokonis as executive director
2024-09-25
ST. LOUIS, MO, September 25, 2024 – After an extensive search, The Academy of Science of St. Louis has named Katherine Polokonis as the next Executive Director.
“After a rigorous search, we are looking forward to Kate’s transformational leadership of The Academy of Science,” said Toni Kutchan, PhD, president of the Board of Trustees of the Academy and member emerita, Donald Danforth Plant Science Center. “Kate's comprehensive experience in STEM education and passion for social equity make her ...
How synchronization supports social interactions
2024-09-25
Turn-taking dynamics of social interactions are important for speech and gesture synchronization, enabling conversations to proceed efficiently, according to a study published September 25, 2024, in the open-access journal PLOS ONE by Tifenn Fauviaux from the University of Montpellier, France, and colleagues.
Conversations encompass continuous exchanges of verbal and nonverbal information. Previous research has demonstrated that gestures and speech synchronize at the individual level. But few studies have investigated how this phenomenon ...
Dogs trained to detect explosives may perform worse in extreme temperature and humidity, taking longer to identify substances and with lower sensitivity
2024-09-25
Dogs trained to detect explosives may perform worse in extreme temperature and humidity, taking longer to identify substances and with lower sensitivity
###
Article URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0306817
Article Title: Environmental effects on explosive detection threshold of domestic dogs
Author Countries: USA
Funding: This research was made possible through funding provided by the DoD Army Research Office under Contract No. W911NF2120124. https://www.arl.army.mil/who-we-are/aro/. SAK’s work was supported by the National Science Foundation ...
Digital biomarkers shedding light on seasonality in mood disorders
2024-09-25
Wrist-based activity sensors worn by individuals with depression and those without over the course of two weeks provided evidence for the relationship between daily sunlight exposure and physical activity, according to a study published September 25, 2024, in the open-access journal PLOS Mental Health by Oleg Kovtun and Sandra Rosenthal from Vanderbilt University, U.S.
Mood disorders are the leading cause of ‘disability’ worldwide. Up to 30 percent of individuals with major depressive disorder and bipolar disorder display a seasonal pattern of symptoms. This phenomenon is now recognized in official diagnostic manuals. Yet very little ...
US politicians support climate action when linked to certain other issues
2024-09-25
The US House of Representatives is more likely to vote on climate action when it is linked with certain other environmental issues, according to a study published September 25, 2024 in the open-access journal PLOS Climate by Kayla Morton of the University of Washington, Seattle and colleagues.
Climate change is a very polarizing issue in US politics. While Congress has not passed many climate-related bills over the past two decades, the House of Representatives has voted on many bills and resolutions related to climate issues, thus providing an opportunity to examine the factors that motivate ...
Mars’ missing atmosphere could be hiding in plain sight
2024-09-25
Mars wasn’t always the cold desert we see today. There’s increasing evidence that water once flowed on the Red Planet’s surface, billions of years ago. And if there was water, there must also have been a thick atmosphere to keep that water from freezing. But sometime around 3.5 billion years ago, the water dried up, and the air, once heavy with carbon dioxide, dramatically thinned, leaving only the wisp of an atmosphere that clings to the planet today.
Where exactly did Mars’ ...
Pitt study identifies potential new treatment for liver fibrosis
2024-09-25
New research from the University of Pittsburgh School of Pharmacy sheds light on the processes that lead to liver fibrosis and suggests a novel treatment approach for this common and serious condition.
Led by senior author Wen Xie, M.D., Ph.D., professor and Joseph Koslow endowed chair of the Department of Pharmaceutical Sciences and co-first authors Hung-Chun Tung, graduate student, and Jong-Won Kim, Ph.D., postdoctoral fellow, the study published today in Science Translational Medicine.
In this Q&A, Xie elaborates ...
Hardest hit by heat
2024-09-25
Each passing year, climate change drives summer temperatures to new extremes, with heat records being shattered one after another. In a new study, scientists from the Max Planck Institute for Demographic Research (MPIDR) have examined how extreme temperatures in the US affect the mortality of people from different racial groups. Risto Conte Keivabu, Ugofilippo Basellini, and Emilio Zagheni (director of MPIDR) analyzed data from 1993 to 2005 and examined racial differences in temperature-related deaths. The study found that both extreme cold (temperatures in the coldest 5%) and extreme heat (temperatures in the hottest 5%) increase mortality rates, with heat disproportionate impacting ...
LAST 30 PRESS RELEASES:
NASA’s Parker Solar Probe makes history with closest pass to Sun
Are we ready for the ethical challenges of AI and robots?
Nanotechnology: Light enables an "impossibile" molecular fit
Estimated vaccine effectiveness for pediatric patients with severe influenza
Changes to the US preventive services task force screening guidelines and incidence of breast cancer
Urgent action needed to protect the Parma wallaby
Societal inequality linked to reduced brain health in aging and dementia
Singles differ in personality traits and life satisfaction compared to partnered people
President Biden signs bipartisan HEARTS Act into law
Advanced DNA storage: Cheng Zhang and Long Qian’s team introduce epi-bit method in Nature
New hope for male infertility: PKU researchers discover key mechanism in Klinefelter syndrome
Room-temperature non-volatile optical manipulation of polar order in a charge density wave
Coupled decline in ocean pH and carbonate saturation during the Palaeocene–Eocene Thermal Maximum
Unlocking the Future of Superconductors in non-van-der Waals 2D Polymers
Starlight to sight: Breakthrough in short-wave infrared detection
Land use changes and China’s carbon sequestration potential
PKU scientists reveals phenological divergence between plants and animals under climate change
Aerobic exercise and weight loss in adults
Persistent short sleep duration from pregnancy to 2 to 7 years after delivery and metabolic health
Kidney function decline after COVID-19 infection
Investigation uncovers poor quality of dental coverage under Medicare Advantage
Cooking sulfur-containing vegetables can promote the formation of trans-fatty acids
How do monkeys recognize snakes so fast?
Revolutionizing stent surgery for cardiovascular diseases with laser patterning technology
Fish-friendly dentistry: New method makes oral research non-lethal
Call for papers: 14th Asia-Pacific Conference on Transportation and the Environment (APTE 2025)
A novel disturbance rejection optimal guidance method for enhancing precision landing performance of reusable rockets
New scan method unveils lung function secrets
Searching for hidden medieval stories from the island of the Sagas
Breakthrough study reveals bumetanide treatment restores early social communication in fragile X syndrome mouse model
[Press-News.org] NEJM: Results from targeted therapy for ulcerative colitis studyPhase ii study led by Cedars-Sinai demonstrates that monoclonal antibody treatment developed by Cedars-Sinai researchers is effective for moderate to severe ulcerative colitis